The initial success of the copyright undeniably reshaped the drug landscape, but investing in companies heavily reliant on generic versions presents a challenging picture. Despite early returns were substantial, the expiration of patents and the appearance of cheaper alternatives have eroded sales. Therefore, a thorough evaluation of present revenu